期刊文献+

新型稀土杂多蓝的合成及其抗艾滋病病毒(HIV-1)活性和毒性研究 被引量:30

Synthesis, Anti-HIV-1 Activity and Toxicity of New Rare Earth-containing Heteropoly Blues
下载PDF
导出
摘要 合成了Keggin结构钨硅、钨锗、钨磷、钨砷两电子及四电子稀土钐盐杂多蓝,铈量滴定及元素分析方法确定了化合物的还原电子数及化学组成,采用 IR,UV-Vis,183 W NMR和ESR等对其结构进行了表征.在人T淋巴细胞 MT-4内,对合成的化合物进行了系统的抗艾滋病毒(HIV-1)活性及毒性测定.发现Keggin结构钨硅、钨锗四电子稀土钐盐杂多蓝具有较强的抗HIV-1活性,其中钨锗酸钐四电子杂多蓝(代号HPBR-2)具有较高的治疗指数. Abstract Two- and four- electron heteropoly blues of samarium-containing polyoxotungstosilicate, poly-oxotungstogermanate, polyoxotungstophosphate and polyoxotungstoarsenate with Keggin structure have been 'synthesized, stoichiometrily determined by elemental analyses and cerimetric titration, and characterized by IR, UV-Vis, 183W NMR and ESR spectra. The anti-HIV activities and toxicities of these compounds have been determined in human T lymph cells MT-4. It has been found that the four-electron heteropoly blue of samarium-containing polyoxotungstogermanate (HPBR-2) has a high therapeusis index. Medicine tolerance test shows that the cells have no obvious resistance to HPBR-2. The half-inhibition concentrations IC50 of HPBR-2 to acutely infected MT-4 cells have no distinct difference between generation 0 and generation 9. The acute toxicity and Ames test of HPBR-2 have also been carried out. HPBR-2 can not mutate the bacterium typhosum. The half toxicity dose LD50 of HPBR-2 orally administrated to mice is 2 988 mg/kg and the maximum tolerance dose is 800 mg/kg, which is 2 000 times as high as the dose orally administrated to the human being(20 mg/50 kg). HPBR-2 belongs to one of the complexes with high safety factors.
出处 《高等学校化学学报》 SCIE EI CAS CSCD 北大核心 2002年第5期777-782,共6页 Chemical Journal of Chinese Universities
基金 国家科技部重大课题(批准号:96-901-01-3OA)资助.
关键词 稀土杂多蓝 合成 抗艾滋病病毒活性 毒性 抗HIV活性 多酸化合物 药性试验 Rare earth-containing heteropoly blues Synthesis Anti-HIV activity Toxicity
  • 相关文献

参考文献27

  • 1Jasmin C., Raybaud N., Chermann J. C. et al.. Biomedicine[J], 1973, 18: 319-327
  • 2Jasmin C., Chermann J. C., Herve G. et al.. J. Natl. Cancer Inst.[J], 1974, 53: 469-479
  • 3Dormont D., Spire B., Barre-Sinoussi F. et al.. Ann. Inst. Pasteur(Paris) Virol.[J], 1985, 13E: 75-83
  • 4Moskovitz B.. Antiviral Chem. Chemother.[J], 1988, 32(9): 1 300-1 303
  • 5Inouye Y., Toutake Y., Kunihara J. et al.. Chem. Pharm. Bull.(Tokyo)[J], 1992, 40: 850-857
  • 6Kim G. S., Judd D. A., Hill C. L. et al.. J. Med. Chem.[J], 1994, 37: 816-820
  • 7Hill C. L., Judd D. A., Boudinot F. D. et al.. International Antiviral News[J], 1995, 3: 159-160
  • 8Weeks M. S., Hill C. L., Schinazi R. F.. J. Med. Chem.[J], 1992, 35: 1 216-1 221
  • 9Judd D. A., Hill C. L., Schinazi R. F.. Antiviral Chem. Chemother.[J], 1994: 410-414
  • 10Yamamoto A., Schols N. D., De Clercq E. et al.. Molpharmacol[J], 1992, 42: 1 109-1 117

二级参考文献18

共引文献112

同被引文献339

引证文献30

二级引证文献106

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部